Login to Your Account



'B' Estrogen Receptor Approach Gains Ground In Breast Cancer

By Randall Osborne


Monday, September 16, 2002
With the dropping of the Avastin (bevacizumab) shoe last week - Genentech Inc. disclosed Phase III data showing the breast cancer drug missed its primary efficacy endpoint - came a renewed focus not only on vascular endothelial growth factor treatments but also on the disease itself. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription